Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 1,300 shares, a decline of 92.0% from the January 31st total of 16,300 shares. Based on an average trading volume of 19,000 shares, the short-interest ratio is presently 0.1 days.
Institutional Trading of Tema Oncology ETF
An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans lifted its stake in shares of Tema Oncology ETF (NASDAQ:CANC – Free Report) by 25.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 399,509 shares of the company’s stock after acquiring an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned 22.96% of Tema Oncology ETF worth $11,351,000 as of its most recent SEC filing.
Tema Oncology ETF Stock Performance
NASDAQ:CANC traded down $0.08 during mid-day trading on Thursday, reaching $25.39. The stock had a trading volume of 10,520 shares, compared to its average volume of 24,227. Tema Oncology ETF has a twelve month low of $23.97 and a twelve month high of $30.11. The business has a 50 day simple moving average of $25.06 and a 200 day simple moving average of $27.03. The firm has a market capitalization of $64.74 million, a price-to-earnings ratio of 26.86 and a beta of 1.11.
Tema Oncology ETF Dividend Announcement
About Tema Oncology ETF
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
See Also
- Five stocks we like better than Tema Oncology ETF
- Best Stocks Under $5.00
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Overbought Stocks Explained: Should You Trade Them?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Basic Materials Stocks Investing
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
